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Abstract: Marine natural products and their synthetic derivatives represent a major source 
of novel candidate anti-cancer compounds. We have recently tested the anti-cancer activity 
of more than forty novel compounds based on an iminoquinone makaluvamine scaffold, 
and have found that many of the compounds exert potent cytotoxic activity against human 
cancer cell lines. One of the most potent compounds, BA-TPQ [(11,12),7-(benzylamino)-
1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one],  was  active  against  a  variety  of 
human cancer cell lines, and inhibited the growth of breast and prostate xenograft tumors 
in mice. However, there was some toxicity noted in the mice following administration of 
the  compound.  In  order  to  further  the  development  of  BA-TPQ,  and  in  a  search  for 
potential sites of accumulation that might underlie the observed toxicity of the compound, 
we accomplished preclinical pharmacological studies of the compound. We herein report 
the in vitro and in vivo pharmacological properties of BA-TPQ, including its stability in 
plasma,  plasma  protein  binding,  metabolism  by  S9  enzymes,  and  plasma  and  tissue 
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distribution. We believe these studies will be useful for further investigations, and may be 
useful for other investigators examining the use of similar compounds for cancer therapy. 
Keywords: marine alkaloid; pharmacokinetics; protein binding; chemotherapy 
Abbreviations:  BA-TPQ:  [(11,12),7-(benzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-
de]quinolin-8(1H)-one];  Cmax:  Maximum  concentration;  Tmax:  Time  at  maximum 
concentration;  T1/2:  Half-life;  AUC:  Area  under  the  concentration-time  curve;  
Cl: Clearance; ADME(T): Absorption distribution metabolism excretion (toxicity) 
 
1. Introduction 
Chemotherapy  is  frequently  used  to  treat  cancer,  particularly  advanced  and  metastatic  cancers. 
Unfortunately,  chemotherapeutic  agents  also  often  exert  their  toxic  effects  in  rapidly-dividing  
non-malignant  cells,  including  cells  of  the  bone  marrow  and  digestive  tract,  and  hair  follicles. 
Moreover,  acquired  and  intrinsic  resistance  to  chemotherapeutic  agents  is  a  major  obstacle  to 
successful cancer treatment. Therefore, there is an urgent need for the development of novel, effective 
therapeutic agents with novel or multiple mechanisms of action, and limited host toxicity.  
Natural  products  have  proven  to  be  an  abundant  source  of  anti-cancer  compounds.  Several 
therapeutic agents currently used in the clinic, such as paclitaxel, doxorubicin, and vincristine, are 
derivatives  of  natural  products.  Among  the  many  natural  compounds  being  evaluated  for  their  
anticancer activity, we and others have observed that compounds of the makaluvamine sub-class have 
especially potent activity [1–4]. Previous studies have shown that therapeutic agents belonging to this 
class exert their anti-cancer activity by inhibiting the enzymatic activity of topoisomerase II [4–6], a 
protein that facilitates the uncoiling of DNA during replication. Topoisomerases (type I and II) have 
proven to be valid targets for therapy, and various clinically-used chemotherapeutic agents, including 
irinotecan (Top I), topotecan (Top 1), and etoposide (Top II), act by inhibiting these enzymes [7,8].  
We recently developed a novel method for the total chemical synthesis of makaluvamine analogs 
[9], and a series of these analogs were screened using the National Cancer Institute panel of 60 human 
cancer cell lines [10]. Although a number of the makaluvamine analogs exhibited anti-cancer activity, 
[11,12],  7-(benzylamino)-1,3,4,8-tetrahydropyrrolo[4,3,2-de]quinolin-8(1H)-one  (BA-TPQ,  Figure  1) 
was the most potent inducer of apoptosis and cell cycle arrest. Moreover, BA-TPQ was found to 
inhibit in vitro growth of prostate and breast cancer cell lines with varying p53 status and to inhibit 
tumor growth in mouse xenograft models of these cancers [11,13].  
Of interest, unlike other makaluvamine compounds (which exert their activity via inhibition of 
topoisomerase II), BA-TPQ appears to exert its anti-cancer effects through multiple mechanisms of 
action, including inhibition of the MDM2 oncoprotein, induction of the DNA damage response, and 
induction of ER (endoplasmic reticulum) stress [11,13]. This novel compound is currently undergoing 
preclinical development as a potential anti-cancer agent. Herein, we report the results of preclinical 
investigations evaluating the pharmacological properties of BA-TPQ in in vitro and in vivo systems. Mar. Drugs 2010, 8  
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We believe that these results will support the future preclinical and clinical evaluation of this synthetic 
iminoquinone as a novel anti-cancer therapeutic.  
Figure 1. Structure of BA-TPQ. 
 
2. Results and Discussion 
2.1. In vitro stability of BA-TPQ in mouse plasma 
We examined the stability of BA-TPQ at 37 ° C, 4 ° C, and −80 ° C in mouse plasma. Under all of 
these conditions, BA-TPQ was very stable at both the low (0.5 µ M) and high (5.0 µ M) concentrations 
over the duration of time examined (Table 1).  
Table 1. Stability of BA-TPQ stored in mouse plasma at different temperatures. 
Temperature  Duration of Time 
0.5 µ M  5.0 µ M 
Amount 
Remaining (%) 
RSD 
(%) 
Amount 
Remaining (%) 
RSD 
(%) 
37 ° C  8 hr  92  0.22  114  0.60 
4 ° C  24 hr  94  12  117  7 
−80 ° C  4 weeks  95  0.36  100  0.13 
RSD (%): Relative standard deviation. 
2.2. In vitro protein binding of BA-TPQ 
Considering the high in vitro stability of BA-TPQ, we believed that the compound might bind 
extensively  to  plasma  proteins.  To  examine  this  possibility,  pooled  murine  plasma  samples  were 
examined for their capacity to bind the iminoquinone at concentrations of 0.5 µ M and 5 µ M. BA-TPQ 
was considerably bound to proteins in mouse plasma, with 63% ±  37.9%; and 74% ±  2.3%; of the 
compound being bound to plasma proteins at concentrations of 0.5 µ M and 5.0 µ M, respectively.  
2.3. S9 metabolism 
To accomplish a preliminary study of the metabolism of BA-TPQ, the compound was incubated 
with S9 fractions containing Phase I and Phase II metabolic enzymes and their co-factors for 15, 30, 
45,  or  60  min.  These  studies  indicated  that  BA-TPQ  undergoes  considerable  metabolism  in  the 
presence  of  both  Phase  I  and  Phase  II  enzymatic  components,  with  approximately  16%  of  the 
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compound being metabolized in each set of reagents (Phase I: 16.8% ±  8.1%; Phase II: 16.4% ±  5.4%) 
during the 60 min incubation (data not shown). 
2.4. Pharmacokinetics of BA-TPQ in mice 
To assess the disposition of BA-TPQ in vivo, pharmacokinetic studies in CD-1 and nude mice were 
conducted. The results are presented in Figures 2 and 3. Pharmacokinetic modeling revealed that a two 
compartment  model  (WinNonlin  6.0  Model  7)  best  fit  the  concentration-time  profile  for  the 
intravenous (IV) administration of BA-TPQ, while a non-compartmental model was used to analyze 
the data obtained following intraperitoneal (IP) administration of the compound. The pharmacokinetic 
parameters of BA-TPQ in CD-1 and nude mice are presented in Tables 2 and 3, respectively. 
Figure  2.  Concentration-time  curves  in  mice  dosed  intravenously  (5  mg/kg)  with  
BA-TPQ. The x- and y-axes are plotted on a logarithmic scale. (Left panel: CD-1 mice;  
Right panel: Nude mice). 
 
Figure 3. Concentration-time curves for BA-TPQ administered by intraperitoneal injection 
(10 mg/kg). The x- and y-axes are plotted on a logarithmic scale. (Left panel: CD-1 mice; 
Right panel: Nude mice). 
  Brain  Heart  Kidneys  Liver  Lungs  Plasma  Spleen 
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Following  a  single  bolus  intravenous  dose  of  BA-TPQ  (5  mg/kg),  there  were  relatively  high 
concentrations  of  the  compound  in  the  plasma  for  the  first  30  minutes  (up  to  0.18  g/mL  and  
0.29 g/mL; Figure 2a and 2b, for CD-1 and nude mice, respectively), with a rapid decline thereafter, 
as indicated by a half-life of 0.14 h and 0.17 h, and a clearance rate of 4.92 ×  10
5 mL/h/kg and  
9.75 ×  10
5 mL/h/kg in CD-1 and nude mice, respectively (Tables 2 and 3). The iminoquinone was no 
longer detectable in plasma after 2 h post-injection in either strain of mice. Conversely, the compound 
was still detectable in the lungs of both CD-1 and nude mice at 24 h after intravenous administration of 
BA-TPQ. The amount of BA-TPQ excreted in the urine of both strains of mice was less than 0.1% of 
the administered dose, and the amount excreted in feces was less than 1% of the administered dose 
(data not shown). 
Table 2. Pharmacokinetic parameters for BA-TPQ following intravenous or intraperitoneal 
injection in CD-1 mice. 
Tissue  Route 
Dose 
(mg/kg) 
R
2* 
Cmax 
(µ g/mL) 
Tmax 
(h) 
T1/2 
(h) 
AUC 
(h· µ g/mL) 
Cl 
(mL/h/kg) 
Plasma 
IV  5  1.00  0.36  -  0.14  0.07  4.92 ×  10
5 
IP  10  0.95  0.11  0.08  0.86  0.11  3.45 ×  10
5 
Heart 
IV  5  1.00  5.34  -  0.13  1.02  0.34 ×  10
5 
IP  10  0.97  7.24  0.08  0.71  4.66  0.08 ×  10
5 
Lungs 
IV  5  1.00  13.05  -  0.26  4.98  0.07 ×  10
5 
IP  10  0.92  12.38  0.08  0.50  9.15  0.04 ×  10
5 
Liver 
IV  5  1.00  0.69  -  0.65  0.65  0.54 ×  10
5 
IP  10  0.88  0.47  0.08  0.24  0.15  2.46 ×  10
5 
Kidneys 
IV  5  1.00  9.68  -  0.20  2.83  0.12 ×  10
5 
IP  10  0.92  8.36  0.25  0.48  8.06  0.04 ×  10
5 
Spleen 
IV  5  1.00  4.59  -  0.27  1.80  0.19 ×  10
5 
IP  10  0.92  23.00  0.08  0.41  11.26  0.03 ×  10
5 
Brain 
IV  5  1.00  0.75  -  0.21  0.22  1.58 ×  10
5 
IP  10  0.97  0.18  0.25  0.83  0.19  1.75 ×  10
5 
Cmax: maximum concentration of the compound observed; Tmax: time when the maximum concentration was 
observed; T1/2: half-life of the compound; AUC: area under the concentration-time curve; Cl: clearance 
*R
2: correlation coefficient of the data for the chosen WinNonlin pharmacokinetic model.  
BA-TPQ plasma concentrations following intraperitoneal dosing (10 mg/kg) were greatest at 15 min 
for CD-1 mice (0.18 µ g/mL) and 1 h for nude mice (0.09 µ g/mL), indicating that BA-TPQ is rapidly 
absorbed  from  the  peritoneal  cavity  (Figure  3a  and  3b).  In  contrast  to  intravenous  dosing, 
intraperitoneal administration generally led to higher AUC values (a measure of the total exposure of 
the plasma or a particular tissue to the drug) in plasma and tissues in both strains, as indicated in 
Tables  2  and  3.  Similar  to  IV  dosing,  low  concentrations  of  BA-TPQ  were  present  in  the  urine 
collected for the first 24 h after dosing, with less than 0.02% of the administered dose being excreted 
in the urine, and less than 1% being excreted in the feces following IP administration of a 10 mg/kg 
dose of the compound (data not shown). The S9 data indicate that the compound is fairly extensively 
metabolized by microsomal enzymes, and the low excretion of the intact compound confirms this.  Mar. Drugs 2010, 8  
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Table 3. Pharmacokinetic parameters for BA-TPQ following intravenous or intraperitoneal 
administration in nude mice. 
Tissue  Route 
Dose 
(mg/kg) 
R
2 
Cmax 
(µ g/mL) 
Tmax 
(h) 
T1/2 
(h) 
AUC 
(h· µ g/mL) 
Cl 
(mL/h/kg) 
Plasma 
IV  5  1.00  0.15  -  0.17  0.04  9.75 ×  10
5 
IP  10  0.95  0.22  0.25  1.17  0.15  2.35 ×  10
5 
Heart 
IV  5  1.00  48.80  -  0.09  6.37  0.05 ×  10
5 
IP  10  0.95  6.38  0.25  0.50  7.63  0.05 ×  10
5 
Lungs 
IV  5  0.95  18.38  -  0.35  9.18  0.04 ×  10
5 
IP  10  0.92  14.75  0.08  0.59  13.16  0.03 ×  10
5 
Liver 
IV  5  1.00  2.71  -  0.18  0.71  0.49 ×  10
5 
IP  10  0.98  4.56  0.08  0.53  2.76  0.13 ×  10
5 
Kidneys 
IV  5  1.00  20.76  -  0.18  5.48  0.06 ×  10
5 
IP  10  0.89  10.84  0.5  0.49  12.62  0.03 ×  10
5 
Spleen 
IV  5  1.00  10.99  -  0.31  4.98  0.07 ×  10
5 
IP  10  0.90  31.22  0.25  1.65  18.29  0.02 ×  10
5 
Brain 
IV  5  1.00  0.62  -  0.38  0.34  1.04 ×  10
5 
IP  10  0.92  0.09  1.00  4.06  0.77  0.39 ×  10
5 
The accumulation of BA-TPQ in the liver of nude mice following intraperitoneal injection was 
much higher (~18-fold) than for CD-1 mice, and the AUC in the brain of the nude mice was also 
increased (~5-fold) compared to CD-1 mice following intraperitoneal injection. Similarly, the exposure 
of the heart of nude mice to BA-TPQ following intravenous injection was approximately 6-fold that of 
CD-1 mice (as measured by AUC; Tables 2 and 3). No strain differences were observed in the plasma 
pharmacokinetic profile of BA-TPQ following either IP or IV administration. In general, the spleen, 
lungs, kidneys and heart had relatively high concentrations of BA-TPQ compared to the plasma, brain 
and liver, regardless of the route of administration or the strain of mice.  
In fact, while there were a few differences between parameters for a few tissues, our data indicated 
that overall there were not any major differences in the distribution of BA -TPQ between the two 
strains of mice following IV or IP administration. The intraperitoneal bioavailability of BA-TPQ in 
CD-1  and  nude  mice  was  74%  and  100%,  respectively.  However,  the  concentrations  detected  in 
plasma were relatively low, and with some variability, so we believe that  the true intraperitoneal 
bioavailability of BA-TPQ is likely closer to that in the CD-1 mice (~70%). 
2.5. Discussion 
Recent studies have demonstrated the ability of BA-TPQ to inhibit the survival of breast, colon, 
prostate, and lung cancer cells in vitro [9–12], and decrease tumor growth in vivo [11,13]. Although a 
number of makaluvamine analogs have been reported to inhibit topoisomerase activity [9], recent data 
indicates that BA-TPQ acts through a variety of mechanisms, leading to the induction of apoptosis and 
inhibition of cell cycle progression [11–13]. Unfortunately, while the compounds were highly effective, 
their use in mice appears to produce systemic toxicity (as indicated by weight loss), especially at the 
higher dose of 10 mg/kg when it was given 3 days/week for several weeks. While the lower doses  
(1 mg/kg and 5 mg/kg) were effective, we would like to be able to increase the therapeutic window of Mar. Drugs 2010, 8  
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the  compound  by  changing  the  dosing  frequency,  the  formulation,  or  other  factors  related  to  the 
distribution of the compound. However, we did not previously have any knowledge about how the 
compound is distributed, and did not observe any gross organ abnormalities that indicated a particular 
target tissue. Our studies reported herein represent an effort to describe the clinical pharmacology of 
BA-TPQ, a novel synthetic marine natural product that may be valuable in cancer therapy. 
Preclinical  pharmacokinetic  studies  aid  in  the  determination  and  optimization  of  various  
therapy-related  parameters,  including  the  dosing,  frequency  of  administration,  formulation,  and 
potential sites of toxicity of the agent. Such information is essential to the development of a compound 
toward Phase I clinical trials. Continuing our pre-clinical work with the compound, we have evaluated 
the pharmacokinetic profile of BA-TPQ in the plasma and tissues of CD-1 and nude mice.  
As a preliminary assessment of potential toxic side effects, including cardio- and hepato-toxicity 
[14,15], we have evaluated the distribution and accumulation of BA-TPQ in plasma and various tissues 
in order to determine whether specific organs are being targeted by this compound. Although most 
pharmacokinetic studies report only the plasma pharmacokinetics of a compound, we believe that it is 
critical  to  assess  the  distribution  of  candidate  anti-cancer  therapeutics  in  various  tissues,  both  to 
determine  potential  sites  of  toxicity  and  to  assess  the  overall  uptake  and  bioavailability  of  the 
compound following administration by different routes or in different formulations.  
The  pharmacokinetic  profile  for  tissues  obtained  in  our  study  suggests  that  there  is  high  drug 
accumulation in the lungs, kidneys, and spleen of the mice, and that it reaches low concentrations in 
the brain. Furthermore, pharmacokinetic modeling confirmed that these tissues exhibited the highest 
drug exposure (AUC), longest half-life, and lowest clearance values, indicating that these organs may 
be  potential sites  of BA-TPQ toxicity  (perhaps  explaining  the toxicity  observed  during the initial 
in vivo studies in tumor-bearing mice), or that they may be ideal tumor sites to target using the drug. 
With regard to toxicity, it appears that BA-TPQ may be less toxic than other natural products from 
marine sponges, because it does not cause death in mice given repeated doses of 10 mg/kg (three times 
per week for up to six weeks [13]) [16,17]. In fact, it appears to have toxicity similar to the marine 
natural products used in the clinic [14,15], suggesting that the compound may be sufficiently tolerable 
even using the current formulation. In addition, while the AUC and clearance for these particular 
tissues may be slightly sub-optimal with regard to toxicity, they are not unusual for such a compound. 
Moreover,  the  data  obtained  during  our  study  were  fairly  consistent  with  other  clinically-used 
compounds, and was in the expected range based on published studies of intravenous infusion of 
Yondelis (trabectedin, ET-743), a marine alkaloid currently in phase II/III clinical trials [18,19].  
We did not examine the distribution of the compound in the mammary tissue or prostate in the 
mice,  as  there are major differences in these tissues between humans and mice (particularly with 
regard to the prostate architecture). However, we did note high levels of the compounds in the lungs, 
suggesting that the compound may be even more effective for lung cancer than for breast and prostate 
cancer. Of interest, our pharmacokinetic data also showed that the compound has an AUC in the brain 
comparable to that in the plasma, indicating that the drug can cross the blood-brain barrier and may be 
effective for neoplasms in the brain. 
While  assessing  the  toxicity  and  ADME  (absorption,  distribution,  metabolism,  excretion)  of  a 
compound in a single mouse strain may be sufficient, we wanted to determine whether there were any 
differences in the disposition of the compound in different strains of mice. In addition to inter-species Mar. Drugs 2010, 8  
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differences in ADME and toxicity (ADMET), there can also be strain-specific differences [20–22]. 
The athymic nude and C57Bl/6 strains of mice are the most frequently employed strains for studying 
the  anti-cancer  activity  of  a  candidate  therapeutic  compound  [23,24].  In  contrast,  CD-1  mice  are 
typically  chosen  for  evaluations  of  the  safety  and  toxicological  profiling  of  candidate  anti-cancer 
agents because of their robust health, availability in large numbers, and their low cost (compared to 
nude and C57Bl/6 mice). Given the possible strain-dependent differences in ADMET, it is unclear 
whether the toxicity and pharmacology of the compound would be the same in mice used for efficacy 
studies and those conventionally used for toxicology and pharmacology studies. In our present study, 
we did not observe any major differences between strains, demonstrating that CD-1 mice can be used 
to predict the pharmacokinetics in nude mice.  
Our study also investigated the pharmacokinetic profile of BA-TPQ following both intravenous  
(5 mg/kg) and intraperitoneal (10 mg/kg) administration. Although intraperitoneal administration is 
rarely used for clinical chemotherapy, it is occasionally used when the cancer site is localized within 
the  intraperitoneal  cavity  (i.e.,  ovarian  cancer).  In  addition,  IP  administration  of  experimental 
therapeutics to animal models is the easiest way to assess the potential anti-cancer activity of the 
compound.  However,  because  intravenous  dosing  is  more  clinically-relevant,  and  because  the 
calculation of various values (e.g., bioavailability) is based upon the results of IV dosing, we also 
examined  the  pharmacokinetics  of  the  compound  following  intravenous  administration.  Our  data 
indicate that BA-TPQ possesses a short plasma half-life, regardless of the route of administration and 
the strain of mouse. We also observed that the bioavailability following IP injection was relatively 
high (>70%). This suggests that, in order to achieve better efficacy in models of cancer (compared to 
our findings in a previous study [13]), a new formulation or better delivery system may be useful.  
Extensive binding of a candidate compound to plasma proteins can greatly impair its biodistribution 
and, consequently, its therapeutic efficacy. Although the unbound fraction of a particular drug can 
traverse  the  cell  membrane  more  easily,  and  thus  more  easily  exert  its  pharmacological  effect, 
decreased  binding  to  plasma  proteins  also  renders  the  compound  more  vulnerable  to  metabolic 
enzymes. Therefore, compounds that are highly bound to proteins display longer half-lives, durations 
of action, and higher volumes of distribution. In the present study, BA-TPQ exhibited considerable 
protein binding, with approximately 70% of the compound bound to plasma proteins. This binding 
may have limited the in vitro degradation of the compound by the S9 enzymes. It is possible that the 
protein binding profile of BA-TPQ will be altered if it is used in combination with other therapeutic 
agents, depending on the affinity of these agents for plasma proteins. Such a possibility will need to be 
examined if the compound is tested in the clinic in order to rule out potential adverse interactions with 
other therapeutic agents or supplements.  
During  the  evaluation  of  the  metabolism  of  BA-TPQ  by  murine  S9  microsomal  fractions,  we 
observed  modest  degradation  of  the  compound.  The  subcellular  (cytosolic  and  microsomal)  liver 
fraction  contains  Phase  I  and  Phase  II  metabolic  enzymes,  including  cytochromes  p450,  flavin 
monooxygenases, and UDP glucuronyl transferases [25], all of which are replicated in the in vitro 
experiment. Our data suggest that BA-TPQ is metabolized by both Phase I and II metabolic enzymes, 
and  that  this  process  may  be  impeded  by  the  considerable  protein  binding  of  the  compound.  No 
specific  peaks  that  seemed  to  correspond  to  unique  metabolites  were  identified  using  the  current 
HPLC method.  Mar. Drugs 2010, 8  
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3. Experimental 
3.1. Test compound, chemicals and reagents  
BA-TPQ was kindly provided by Dr. Sadanandan Velu (University of Alabama at Birmingham). 
Acetonitrile and methanol were purchased from Fisher Scientific (Atlanta, GA). All other chemicals 
were purchased from Sigma Chemical Company (St. Louis, MO). Heparinized samples of non-Swiss 
albino mouse plasma were obtained from Lampire Biological Laboratories (Pipersville, PA). Hepatic 
S9 fractions (20 mg/mL) from male ICR/CD-1 mice were purchased from Celsis In Vitro Technologies 
(Chicago, IL). All chemicals and solvents used for sample preparation and high-performance liquid 
chromatography (HPLC) analysis were of analytical grade.  
3.2. Instrumentation and chromatographic conditions 
A high performance liquid chromatography (HPLC) analytical method for BA-TPQ quantitation 
was previously developed and validated. The HPLC system consisted of an Agilent 1120 Compact 
HPLC system equipped with a UV detector. Separation and quantification of the test compound was 
achieved using a Zorbax SB-C18 (5 μm, 4.6 ×  150 mm) analytical column (Agilent Technologies, CA, 
USA) protected by a SB-C18 guard column (Agilent Technologies, CA, USA). The instrument was 
interfaced with the EZ-Chrom Elite Compact software provided by Agilent Technologies. The mobile 
phase was composed of 28.0% acetonitrile containing 0.03% formic acid. The column temperature was 
set at 35 ° C under a gradient flow rate which was maintained at 0.5 mL/min for 7 min, increased to 
1.2 mL/min at 8 min, and finally decreased to 0.5 mL/min at 11 min for the remainder of the 16 min 
run. The detection wavelength was set at 346 nm and 50 µ L of each sample was injected into the 
HPLC system.  
3.3. Stability in mouse plasma 
The stability of BA-TPQ was evaluated at two concentrations (0.5 and 5.0 M). The compound was 
incubated under the following conditions: 37 ° C for 0, 1, 2, 4, and 8 h; 4 ° C for 0, 1, 4, 8, and 24 h; and 
−80  ° C  for  0,  1, 2, and  4 weeks.  At the designated  time  points,  the samples  were  extracted  and 
analyzed  using  the  established  HPLC  analytical  method.  The  stability  of  the  iminoquinone  was 
assessed  by  comparing  the  initial  concentration  (time  0)  with  the  final  concentration  following 
incubation of the compound at the noted temperatures, and expressing this difference as a percentage 
of the initial concentration.  
3.4. Binding to mouse plasma proteins 
The  extent  of  binding  to  mouse  plasma  proteins  by  BA-TPQ  was  determined  using  a  
micro-ultrafiltration system as previously described [26]. BA-TPQ was dissolved in methanol and 
added to pooled mouse plasma to yield final concentrations of 0.5 M and 5.0 M. Control solutions 
were prepared in methanol to account for non-specific binding of BA-TPQ to the filter membranes. 
Duplicate preparations of each concentration were incubated at 37 ° C for 1 h, before being placed into 
the  sample  reservoirs  of  Amicon  Centrifree®  ultrafiltration  tubes  (30  kDa  exclusion;  Millipore Mar. Drugs 2010, 8  
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Corporation, Bedford, MA, USA). The filter systems were then centrifuged at 3000 g (37 ° C) for 
30 min or until no solution remained in the reservoir. Aliquots were taken from each filtrate and 
analyzed using the validated HPLC method. The concentrations of the unfiltered plasma and control 
preparations  were  also  determined using the same  protocol  and  expressed  as the “total  drug” (T) 
present, while the amounts of BA-TPQ present in the filtrates were designated as “free drug” (F). The 
percentage of BA-TPQ bound to plasma proteins was calculated as follows: 
Percent Bound = [(T − F)/T] ×  100  (1)  
3.5. S9 metabolism 
A preliminary study of the metabolism of BA-TPQ was done using murine hepatic S9 fractions 
containing Phase I and II metabolic enzymes. The reaction mixture contained 10 µ M BA-TPQ (in 
methanol), 1 mg/mL S9 and 100 mM Tris buffer (pH 7.4). (Experimental controls did not contain the 
hepatic S9 fractions.) Metabolic reactions were initiated by adding NADPH-regenerating systems to 
the reaction mixtures, and samples were incubated in a water bath at 37 ° C. Duplicate aliquots of the 
mixtures were taken at 0, 15, 30, 45, and 60 min, and the samples were processed and analyzed. The 
percent  of  BA-TPQ  that  was  metabolized  by  Phase  I  and  Phase  II  enzymes  was  calculated  
by  comparing  the  initial  concentration  of  the  iminoquinone  to  the  measured  concentration 
following incubation. 
3.6. Pharmacokinetic studies  
3.6.1. Animals  
Female ICR/CD-1 (18–20 g) mice were purchased from Harlan Laboratories (Indianapolis, IN), and 
female  nude  mice  (nu/nu;  4–6  weeks)  were  purchased  from  Frederick  Cancer  Research  and 
Development  Center  (Frederick,  MD).  All  animal  use  and  care  procedures  were  approved  by  the 
Institutional Animal Care and Use Committee (IACUC) of the University of Alabama at Birmingham. 
All  animals  were  fed  with  commercial  diet  and  water  ad  libitum  and  were  on  an  alternating  
12 h light/dark cycle. 
3.6.2. Animal dosing and sampling 
CD-1  and  nude  mice  were  randomly  divided  into  groups  of  three,  and  were  dosed  either 
intravenously (5 mg/kg) or intraperitoneally (10 mg/kg) with BA-TPQ in PEG 400:ethanol:0.9% saline 
(57.1%:14.3%:28.6%). Before dosing, and at 5, 15, 30, 60 min, and 2, 4, 8, and 24 h after dosing, 
groups of animals (three/time point) were anesthetized, and blood was collected from the retro-orbital 
sinus into heparinized tubes. Plasma was obtained by centrifuging the blood samples at 14,000 rpm for 
15 min. BA-TPQ was then extracted from plasma and stored at −80 ° C. The brain, heart, kidneys, 
liver,  lungs,  and  spleen  were  also  collected  at  the  same  time  points  during  necropsy,  blotted  on 
Whatman  No.  1  filter  paper,  trimmed  of  extraneous  fat  and  connective  tissue,  weighed,  and 
homogenized in phosphate-buffered saline. The resulting homogenates were stored at −80 °C  until 
further  processing  and  analysis.  Urine  and  feces  were  collected  for  24  hr  from  mice  housed  in Mar. Drugs 2010, 8  
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metabolic cages. After collection, the cages were also washed twice with 200 L PBS, and the washes 
were collected and analyzed separately. The total urine was determined as the amount from the urine 
plus washes 1 and 2. Feces were homogenized in PBS, then extracted using the same procedure used 
for tissues. 
3.6.3. Sample preparation 
Six hundred microliters of acetonitrile was added to 200 μL of plasma, urine, cage washes (first and 
second), or tissue/feces homogenate in an Eppendorf tube to precipitate proteins. After centrifugation 
at 14,000 rpm for 10 min, the supernatant was transferred to a glass tube and evaporated to dryness 
using  a  TurboVap®  LV  Concentration  Workstation  (Caliper  Lifesciences,  Hopkinton,  MA).  The 
residue was reconstituted with 500 μL ethyl acetate, sonicated for 10 min, and vortexed for 10 sec. 
Samples were then centrifuged again and the resulting supernatant was transferred to a new glass tube 
and evaporated to dryness. Finally, samples were reconstituted in 100 μL mobile phase, and 50 μL was 
injected into the HPLC system for analysis.  
3.6.4. Pharmacokinetic analysis 
The  averages  of  the  BA-TPQ  concentration  in  plasma  and  tissues  following  intravenous  and 
intraperitoneal administration to three animals per time point were used for pharmacokinetic analyses 
using  a  two-compartmental  model  and  a  non-compartment  model,  respectively.  The  following 
pharmacokinetic parameters were estimated using Phoenix WinNonlin 6.0 (Mountain View, CA): area 
under  the  concentration-time  curve  (AUC,  h· µ g/mL),  half-life  (T½,  h),  maximum  concentration  
(Cmax,  µ g/mL),  time  of  the  maximum  concentration  (Tmax,  h),  and  clearance  (CL,  mL/h/kg),  as 
applicable. Bioavailability (X) was calculated as X= [AUCip ×  doseiv]/[AUCiv ×  doseip].  
4. Conclusions 
In conclusion, the present study has uncovered the preclinical in vitro and in vivo pharmacological 
properties  of  a  novel  analog  of  a  natural  product  derived  from  a  marine  sponge.  Further  studies 
employing mass spectrometry would be informative in order to identify whether there are specific 
metabolites of the compound that are responsible for its activity and/or toxicity. Moreover, since the 
activity of metabolic enzymes may vary between species, the metabolism of BA-TPQ by S9 fractions 
from  other  species,  including  humans,  should  also  be  investigated  during  the  further  pre-clinical 
evaluation of the compound. However, collectively, the data presented herein provide the basis for 
future evaluations of the pharmacology and toxicology of BA-TPQ as it continues to be developed as a 
novel anti-cancer therapeutic agent. 
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